RESUMEN
Methdilazine (Md) could inhibit various Mycobacterium spp. at 5-15 micrograms/ml concentrations in vitro as well as in vivo. When Md was tested in combination with streptomycin (Sm), rifampicin (Rf) or methyl-DOPA (m-D), it showed synergistic effects only with respect to methyl-DOPA.
Asunto(s)
Antagonistas de los Receptores Histamínicos H1/farmacología , Mycobacterium/efectos de los fármacos , Fenotiazinas/farmacología , Animales , Interacciones Farmacológicas , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Humanos , Masculino , Metildopa/farmacología , Ratones , Ratones Endogámicos , Pruebas de Sensibilidad Microbiana , Fenotiazinas/uso terapéutico , Rifampin/farmacología , Estreptomicina/farmacología , Tuberculosis/tratamiento farmacológicoRESUMEN
The effect of augmentin alone and in combination with various beta-lactam antibiotics was studied against a pathogenic Mycobacterium, M. marinum. The in vitro studies did not reveal any additional advantage over that found with augmentin alone and this antibiotic seemed considerably inhibitory to M. marinum at < 1 microgram/ml concentration. In vivo, the effects of augmentin on experimentally produced lesions in the mouse foot pads (MFPs) showed a significant regression of the lesions, which was compatible with an early disappearance of M. marinum from the MFP, in contrast with those of the untreated, control animals.